DSIP Beyond Sleep: The Stress, Cortisol, Pain and Withdrawal Studies

LynxLab · 24 October 2026 · 8 min read

What the DSIP studies on ACTH and cortisol, emotional stress, chronic pain and alcohol or opiate withdrawal found, and why the peptide was never taken further.

Photo: Adrian Sulyok, Unsplash

Most people meet DSIP through its name. Delta sleep-inducing peptide sounds like a single-purpose molecule, and the sleep story is the one that gets retold.

Yet within a few years of the 1977 discovery, the people studying dsip had moved on to the adrenal axis, to stress, to opiate withdrawal and to chronic pain. Those studies are smaller, stranger and less often read. They are also the reason the peptide is still being made.

Why researchers looked past sleep so quickly

The early rabbit data showed a change in EEG delta power, not a knock-out effect, and the dose-response curve was U-shaped. Markus Graf and Abba Kastin, reviewing the field in 1984, listed what else the peptide had been seen to do: shift neurotransmitter levels in the brain, alter circadian and locomotor patterns, change hormone levels, affect psychological performance, and modify the action of other drugs, including their withdrawal.

That list came from a review in Neuroscience and Biobehavioral Reviews, which also recorded that DSIP-like material had been found by radioimmunoassay in the brain, in peripheral organs and in the plasma of several mammals. A peptide turning up in the adrenal gland and the pituitary is not behaving like a pure sleep signal.

Guido Schoenenberger, the Basel biochemist who had sequenced the peptide, began describing it as a "programming" or modulating substance rather than a hypnotic. The vocabulary was vague, but it opened the door to a decade of work on stress hormones.

DSIP and the stress axis in animals

The hypothalamic-pituitary-adrenal axis runs in three steps. Corticotropin-releasing factor (CRF) from the hypothalamus tells the pituitary to release ACTH, and ACTH tells the adrenal cortex to release cortisol, or corticosterone in rodents.

In 1985 a group writing in Neuroendocrinology tested where DSIP acted. Rats were pre-treated with chlorpromazine, morphine and pentobarbital to silence their own CRF, then given CRF to stimulate corticosterone release. Intravenous DSIP at 5 to 30 micrograms per kilogram significantly reduced the corticosterone response.

The telling control was ACTH. When the researchers bypassed the pituitary and injected ACTH directly, DSIP had no effect on corticosterone. Their conclusion was that the peptide attenuated CRF at the level of the pituitary, not the adrenal gland.

Russian work extended this to emotional stress. Konstantin Sudakov's group at the Anokhin Institute in Moscow sorted Wistar rats into stress-resistant and stress-predisposed groups by their open-field behaviour, then subjected them to an hour of restraint with intermittent foot shocks. Published in the journal Stress in 2001, the study used Fos protein as a marker of neuronal activation.

Intraperitoneal DSIP at 30 micrograms per kilogram reduced the stress-induced rise in Fos-positive cells in the paraventricular nucleus and the septum, with the clearest effect in the predisposed rats. The paper compared DSIP with an ACTH(4-10) analogue and found the two peptides acted on different brain regions. For anyone sourcing research-grade dsip for stress-axis work, this remains one of the few mechanistic animal studies with a clear design.

What the human cortisol studies found

The human evidence runs in the opposite direction, which is the most important thing to know about it.

In 1989 Anders Bjartell and colleagues reported in Psychoneuroendocrinology a reduction of immunoreactive ACTH in plasma following intravenous injection of DSIP in man. The same group had earlier found DSIP-like immunoreactivity in the pituitary cells that make ACTH and in the adrenal medulla, so the result fitted a tidy story.

Ernst Späth-Schwalbe, Jan Born and colleagues at the University of Lübeck set out to test the story properly. Their 1995 paper, also in Psychoneuroendocrinology, ran two experiments in healthy young men. In the first, five men per condition received human CRH at two doses, with DSIP or placebo infused alongside. In the second, ten men received a 4 mg intravenous infusion of DSIP around a midday meal, which produces a natural surge of ACTH and cortisol.

The ACTH and cortisol responses to CRH were "almost identical" with DSIP and placebo. The meal-related surge was unaffected. The authors wrote that their data "do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man".

Two things are worth holding onto here. The rat data were obtained in animals whose own CRF had been chemically suppressed, which is a long way from a healthy human at lunchtime. And a single negative study in 15 men does not rule out an effect, but it does mean that the claim that buy dsip searches often turn up, that the peptide "lowers cortisol", has not been shown in people.

The Geneva withdrawal studies

The most dramatic DSIP papers came from René Tissot's department at the University of Geneva. Tissot had shown in animals that morphine, alcohol, pentobarbital and DSIP all produced slow-wave sleep with spindles when injected into the brainstem recruiting system, and that naloxone reversed all four. He concluded that DSIP had some opiate-receptor agonist activity and might ease withdrawal.

Pierre Dick and colleagues tested this on the ward. Their 1984 report in European Neurology covered 107 inpatients in withdrawal, 47 from alcohol and 60 from opiates, treated with intravenous DSIP as the sole therapy. The outcome measure was the clinical judgement of the physician and the nursing staff.

In 97% of the opiate patients and 87% of the alcohol patients the authors reported that symptoms disappeared or improved markedly and rapidly. Anxiety took longer to settle. Opiate patients needed more injections than alcohol patients. The only side effect noted was headache in a few people.

Read as a sceptic would, the limitations are obvious. There was no placebo group, no blinding, and no rating scale. Roughly a fifth of the opiate group did not meet the criteria for evaluation. The study has never been repeated under controlled conditions, which is why a dsip uk buyer in 2026 will find the same 1984 numbers quoted everywhere and nothing newer.

The chronic pain pilot and the depression signal

Wolfgang Larbig's group at Tübingen, working with Schoenenberger, ran a small pilot study in patients with chronic pain, published in European Neurology in 1984. Seven patients took part, with diagnoses spanning migraine, vasomotor headache, chronic tinnitus and psychogenic pain attacks.

The protocol was intravenous DSIP on five consecutive days followed by five further injections at 48 to 72 hour intervals. Pain levels during the follow-up period were compared with the patients' own baseline history. The authors reported significantly lower pain in six of the seven patients, and noted a simultaneous reduction in the depressive symptoms that accompanied the pain.

The depression observation is the part later authors have found most interesting, because it chimes with the Geneva finding that anxiety and mood shifted in withdrawal patients. But seven patients, no placebo and a before-and-after comparison is a pilot, not a trial. Nobody funded the trial. Anyone searching for a delta sleep-inducing peptide supplier today should know that this 1984 paper is still the entire published human pain literature.

Why DSIP is still an orphan peptide

Four things kept DSIP in the laboratory. First, no gene, precursor protein or receptor has ever been found, a point Vladimir Kovalzon and Tatyana Strekalova made in their 2006 review, "a still unresolved riddle", in the Journal of Neurochemistry. Without a receptor there is no target to screen against and no simple way to explain the mixed results.

Second, the human studies were small, mostly uncontrolled and clustered in two or three European departments between 1981 and 1995. Third, the one well-designed placebo-controlled hormone study was negative. Fourth, the sequence has been public since 1977, which left little commercial incentive for a company to pay for phase 2 and 3 trials.

The result is a peptide with a rich animal literature, a Russian clinical product called Deltaran, and a thin, old human record. Searches of the published literature turn up no controlled phase 2 or phase 3 trial of DSIP in any indication.

In the UK the peptide has no MHRA marketing authorisation and is supplied for laboratory research only. LynxLab stocks dsip 5mg for research use at £13.95 a vial, tested to 99% purity with the lab report on the product page. Batch lab reports are published for every product. For the first half of the story, the Basel isolation and the sleep trials, see our piece on the 1977 discovery of DSIP.

Frequently asked questions

Does DSIP lower cortisol?

In rats whose own CRF had been suppressed, DSIP reduced the corticosterone response to injected CRF in a 1985 study. In healthy men, a placebo-controlled study from Lübeck in 1995 found that a 4 mg intravenous infusion had no effect on ACTH or cortisol responses to CRH or to a midday meal. The human claim is unsupported.

What did the DSIP withdrawal studies show?

A 1984 Geneva study gave intravenous DSIP to 107 inpatients withdrawing from alcohol or opiates and reported marked improvement in 87% and 97% respectively, judged clinically by staff. There was no placebo group or blinding, and the study has not been repeated under controlled conditions.

Was DSIP ever tested for chronic pain?

Once, in a 1984 Tübingen pilot of seven patients with migraine, vasomotor headache, tinnitus or psychogenic pain. Six of seven reported lower pain after a course of intravenous injections compared with their own baseline, with a parallel fall in depressive symptoms. No controlled pain trial followed.

Why is DSIP called an orphan research peptide?

Because it has no identified gene, precursor or receptor, no commercial sponsor, and no controlled phase 2 or 3 trial in any indication. The human data are small studies from the 1980s and one negative hormone study from 1995, so it remains a laboratory compound rather than a medicine.

Sources

Research use only

DSIP from LynxLab

5mg vials from £13.95. ≥99% purity, lab report on the page. Same-day dispatch, UK stock.

Buy DSIP